FY2022 Earnings Estimate for MEI Pharma, Inc. Issued By Oppenheimer Holdings (MEIP)
MEI Pharma, Inc. (NASDAQ:MEIP) – Analysts at Oppenheimer Holdings issued their FY2022 EPS estimates for MEI Pharma in a note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann anticipates that the company will post earnings per share of ($1.05) for the year. Oppenheimer Holdings currently has a “Buy” rating and a $7.00 target price on the stock.
MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings data on Tuesday, September 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The company had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.60 million. MEI Pharma had a return on equity of 5.26% and a net margin of 11.48%. ILLEGAL ACTIVITY NOTICE: “FY2022 Earnings Estimate for MEI Pharma, Inc. Issued By Oppenheimer Holdings (MEIP)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/08/fy2022-earnings-estimate-for-mei-pharma-inc-issued-by-oppenheimer-holdings-meip.html.
Several other equities research analysts also recently weighed in on MEIP. Zacks Investment Research downgraded shares of MEI Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, July 20th. Cann reiterated a “buy” rating and set a $6.50 target price on shares of MEI Pharma in a research note on Monday, June 26th.
MEI Pharma (MEIP) traded up 1.40% during mid-day trading on Friday, reaching $2.89. The company had a trading volume of 425,520 shares. The firm has a market capitalization of $106.27 million, a PE ratio of 85.00 and a beta of 1.65. The stock’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.11. MEI Pharma has a 52 week low of $1.34 and a 52 week high of $3.26.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in shares of MEI Pharma by 58.6% during the first quarter. Renaissance Technologies LLC now owns 1,564,428 shares of the company’s stock worth $2,534,000 after buying an additional 578,009 shares during the period. Vanguard Group Inc. boosted its stake in shares of MEI Pharma by 12.3% during the second quarter. Vanguard Group Inc. now owns 740,580 shares of the company’s stock worth $1,770,000 after buying an additional 81,308 shares during the period. FMR LLC boosted its stake in shares of MEI Pharma by 11.2% during the first quarter. FMR LLC now owns 351,000 shares of the company’s stock worth $569,000 after buying an additional 35,476 shares during the period. OxFORD Asset Management LLP boosted its stake in shares of MEI Pharma by 116.2% during the second quarter. OxFORD Asset Management LLP now owns 235,025 shares of the company’s stock worth $562,000 after buying an additional 126,303 shares during the period. Finally, ClariVest Asset Management LLC acquired a new stake in shares of MEI Pharma during the second quarter worth about $480,000. Institutional investors and hedge funds own 18.00% of the company’s stock.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.